Innocan Pharma Corporation reported positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs. The drug was administered in three ascending doses, and the animals were closely monitored over a 28-day period for key safety parameters. These included clinical observations, vital signs, blood parameters, and local injection site reactions.

Encouragingly, no adverse events were recorded during the study. All animals exhibited normal weight gain and demonstrated excellent tolerance to the drug, with no local reactions observed at any of the administered dose sites. Minipigs are breeds of miniature domestic pigs which are recognized by the FDA as a robust translational model due to their anatomical, physiological, and biochemical similarities to humans.

They provide valuable insights into pharmacokinetics, toxicity, and drug efficacy. LPT-CBD is an innovative injectable liposomal formulation designed for the sustained release of CBD, targeting the treatment of chronic pain. Previous preclinical studies in various animal models have demonstrated prolonged CBD pharmacokinetics, delivering long-term efficacy.